1.
Fatty acid synthase as a potential therapeutic target in cancer
by Flavin, Richard
Future oncology (London, England), 2010-04-01, Vol.6 (4), p.551-562
2.
Stage-specific follicular extracellular vesicle uptake and regulation of bovine granulosa cell proliferation
by Hung, Wei-Ting
Biology of reproduction, 2017-10, Vol.97 (4), p.644-655
3.
Signaling and Function of Interleukin-2 in T Lymphocytes
by Ross, Sarah H
Annual review of immunology, 2018-04-26, Vol.36 (1), p.411-433
4.
The PI3K AKT Pathway as a Target for Cancer Treatment
by Mayer, Ingrid A
Annual review of medicine, 2016-01-14, Vol.67 (1), p.11-28
5.
NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
by Yu, Zhiyun
Cancer letters, 2015, Vol.367 (1), p.58-68
7.
Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
by Sánchez-Hernández, Irene
Cancer letters, 2012, Vol.314 (2), p.244-255
9.
PI3K-Akt pathway: its functions and alterations in human cancer
by Osaki, M
Apoptosis (London), 2004-11, Vol.9 (6), p.667-676
10.
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
by Okkenhaug, Klaus
Annual review of immunology, 2013-03-21, Vol.31 (1), p.675-704
11.
The anti-apoptotic and anti-autophagic effects of EPO through PI3K/Akt/mTOR signaling pathway in MAC-T cells
by Liu, Jingsong
Research in veterinary science, 2022-06-12, Vol.149, p.1-10
12.
Novel PIK3CD mutations affecting N-terminal residues of p110δ cause APDS1 in humans
by Takeda, Andrew J Andrew J
Journal of allergy and clinical immunology, 2017-04-13, Vol.140 (4), p.1152-1156.e10
13.
Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway
by Kumar, Dhruv
Cancer letters, 2013, Vol.343 (2), p.179-189
14.
Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells
by Xavier, Cristina P.R
Cancer letters, 2009, Vol.281 (2), p.162-170
15.
LncRNA PCAT7 promotes the malignant progression of breast cancer by regulating ErbB/PI3K/Akt pathway
by Zhou, Jiaoqun
Future oncology (London, England), 2021-02, Vol.17 (6), p.701-710
16.
Alpelisib in the treatment of metastatic HR+ breast cancer with
Future oncology (London, England), 2021-01-01, Vol.17 (1), p.13-36
17.
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study
by Coulter, Tanya I., MRCPI
Journal of allergy and clinical immunology, 2016, Vol.139 (2), p.597-606.e4
18.
LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes
by Yan, Jin
Tumor biology, 2016-11-30, Vol.37 (12), p.16345-16355
19.
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations
by Mavratzas, Athanasios
Future oncology (London, England), 2021-01, Vol.17 (1), p.13-36
20.
CD19 controls TLR9 responses in human B cells
by Morbach, Henner Henner
Journal of allergy and clinical immunology, 2015-10-21, Vol.137 (3), p.889-898.e6
